US 11,666,642 B2
PDE5 compositions and methods for immunotherapy
Vipin Suri, Belmont, MA (US); Byron Delabarre, Arlington, MA (US); Michael N. Gladstone, Cambridge, MA (US); Celeste Richardson, Brookline, MA (US); Brian Dolinski, Cambridge, MA (US); Abhishek Kulkarni, Brookline, MA (US); Mara Christine Inniss, Beverly, MA (US); Dexue Sun, Cambridge, MA (US); Dan Jun Li, Cambridge, MA (US); Grace Y. Olinger, Cambridge, MA (US); and Scott Francis Heller, Stoughton, MA (US)
Assigned to OBSIDIAN THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Obsidian Therapeutics, Inc., Cambridge, MA (US)
Filed on Feb. 1, 2022, as Appl. No. 17/649,592.
Application 17/649,592 is a continuation of application No. 16/621,593, granted, now 11,241,485, previously published as PCT/US2018/037005, filed on Jun. 12, 2018.
Claims priority of provisional application 62/555,313, filed on Sep. 7, 2017.
Claims priority of provisional application 62/523,862, filed on Jun. 23, 2017.
Claims priority of provisional application 62/523,850, filed on Jun. 23, 2017.
Claims priority of provisional application 62/518,078, filed on Jun. 12, 2017.
Prior Publication US 2023/0074330 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/46 (2006.01); A61P 35/00 (2006.01); A61K 31/4985 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C12N 9/16 (2006.01); A61K 39/00 (2006.01); A61P 37/04 (2006.01); C07K 19/00 (2006.01)
CPC A61K 38/465 (2013.01) [A61K 31/4985 (2013.01); A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C12N 9/16 (2013.01); C12Y 301/04035 (2013.01); A61K 2039/505 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 26 Claims
 
1. A composition comprising an effector module, said effector module comprising a stimulus response element (SRE) and at least one payload which is operably linked to said SRE, wherein the SRE comprises a destabilizing domain (DD), wherein the DD comprises the catalytic domain of a human cGMP-specific 3′,5′-cyclic phosphodiesterase (hPDE5), wherein the DD comprises SEQ ID NO: 3, and wherein the DD further comprises a mutation in the amino acid at the position corresponding to amino acid 732 (R732) of SEQ ID NO: 1.